A Comprehensive Overview of Allergen-specific Immunotherapy Types, Recombinant and Natural Extract Allergens in the Diagnosis and Treatment of Allergies
-
Soheila Asoudeh Moghanloo
,
Mohsen Forouzanfar
,
Mojtaba Jafarinia
,
Mohammad Reza Fazlollahi
,
Gholam Ali Kardar
Abstract
Allergen-specific immunotherapy (AIT) involves administering allergen extracts. It is used to desensitize allergic patients. Herbal allergen extracts that are optimum in efficacy and fewest in side effects are still challenging to produce. To overcome these limitations, oral immunotherapy, epicutaneous immunotherapy, intralymphatic immunotherapy, and artificial recombinant allergen preparations have been evaluated. Recombinant allergens have become more popular with the development of molecular diagnostics and therapeutics. Besides food and drug allergens, pollen, fungal spores, and other allergens have been studied. Based on related clinical studies, this comprehensive overview will present the latest perspectives on AIT methods and available allergenic products, as well as discuss the challenges and opportunities for treating allergic disorders.
1.Dougherty JM, Alsayouri K, Sadowski A. Allergy. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
2.Migueres M, Dávila I, Frati F, Azpeitia A, Jeanpetit Y, Lhéritier-Barrand M, et al. Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease. Clin Transl Allergy. 2014;4:16.
3.Pawankar R, Baena-Cagnani CE, Bousquet J, Canonica GW, Cruz AA, Kaliner MA, et al. State of world allergy report 2008: allergy and chronic respiratory diseases. World Allergy Organ J. 2008;1(6 Suppl):S4-S17.
4.Valenta R, Karaulov A, Niederberger V, Zhernov Y, Elisyutina O, Campana R, et al. Allergen extracts for in vivo diagnosis and treatment of allergy: is there a future? The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(6):1845-55. e2.
5.Niederberger V, Eckl-Dorna J, Pauli G. Recombinant allergen-based provocation testing. Methods. 2014;66(1):96-105.
6.Eckl-Dorna J, Klein B, Reichenauer TG, Niederberger V, Valenta R. Exposure of rye (Secale cereale) cultivars to elevated ozone levels increases the allergen content in pollen. Journal of Allergy and Clinical Immunology. 2010;126(6):1315-7.
7.Forte G, Petrucci F, Bocca B. Metal allergens of growing significance: epidemiology, immunotoxicology, strategies for testing and prevention. Inflammation & allergy drug targets. 2008;7(3):145-62.
8.Bacher P, Scheffold A. The effect of regulatory T cells on tolerance to airborne allergens and allergen immunotherapy. The Journal of allergy and clinical immunology. 2018;142(6):1697-709.
9.Burge HA, Rogers CA. Outdoor allergens. Environmental health perspectives. 2000;108 Suppl 4(Suppl 4):653-9.
10.Ring J, Gutermuth J. 100 years of hyposensitization: history of allergen‐specific immunotherapy (ASIT). Allergy. 2011;66(6):713-24.
11.Ostrom NK, editor The history and progression of treatments for allergic rhinitis. Allergy & Asthma Proceedings; 2014.
12.Vatti RR, Ali F, Teuber S, Chang C, Gershwin ME. Hypersensitivity reactions to corticosteroids. Clinical reviews in allergy & immunology. 2014;47(1):26-37.
13.Settipane RA, Schwindt C. Allergic rhinitis. American journal of rhinology & allergy. 2013;27(3_suppl):S52-S5.
14.Vieths S, Zimmer J, Bridgewater J, Ferreira F, van Ree R, Rabin RL. The History, Present and Future of Allergen Standardization in the United States and Europe. Frontiers in immunology. 2021:3648.
15.Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Current opinion in immunology. 1995;7(6):751-6.
16.Valenta R. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy. 1999;29:896-904.
17.Kucuksezer UC, Ozdemir C, Cevhertas L, Ogulur I, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergology international : official journal of the Japanese Society of Allergology. 2020;69(4):549-60.
18.Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17-.
19.Noon L. Prophylactic inoculation against hayfever. Lancet i: 1572–1573. Freeman J.(1911) Further observations of the treatment of hay fever by …; 1911.
20.Johansson S. The history of IgE: from discovery to 2010. Current allergy and asthma reports. 2011;11(2):173-7.
21.Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children—a 14-year study. Pediatrics. 968;42(5):793-802.
22.Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. New England Journal of Medicine. 1978;299(4):157-61.
23.Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy. 1997;27(8):860-7.
24.Makatsori M, Pfaar O, Lleonart R, Calderon MA. Recombinant allergen immunotherapy: clinical evidence of efficacy--a review. Curr Allergy Asthma Rep. 2013;13(4):371-80.
25.Gold MJ, Antignano F, Halim TY, Hirota JA, Blanchet M-R, Zaph C, et al. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. Journal of Allergy and Clinical Immunology. 2014;133(4):1142-8. e5.
26.Scadding G, Durham S. Mechanisms of sublingual immunotherapy. The Journal of asthma : official journal of the Association for the Care of Asthma. 2009;46(4):322-34.
27.Scadding G, Durham S. Mechanisms of sublingual immunotherapy. Journal of Asthma. 2009;46(4):322-34.
28.Morris AE, Marshall GD. Safety of allergen immunotherapy: a review of premedication and dose adjustment. Immunotherapy. 2012;4(3):315-22.
29.Baron‐Bodo V, Batard T, Nguyen H, Frereux M, Horiot S, Harwanegg C, et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clinical & Experimental Allergy. 2012;42(10):1510-8.
30.Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. Journal of Allergy and Clinical Immunology. 2010;126(5):969-75.
31.Yang L, Zhu R. Immunotherapy of house dust mite allergy. Hum Vaccin Immunother. 2017;13(10):2390-6.
32.Cox L. Biologics and Allergy Immunotherapy in the Treatment of Allergic Diseases. Immunology and Allergy Clinics. 2020;40(4):687-700.
33.van de Veen W, Akdis M. Tolerance mechanisms of AIT. Allergy. 2020;75(5):1017-8.
34.Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. Journal of allergy and clinical immunology. 2004;113(6):1117-21.
35.Windom HH, Lockey RF. An update on the safety of specific immunotherapy. Current opinion in allergy and clinical immunology. 2008;8(6):571-6.
36.Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunology today. 1991;12(8):256-7.
37.Lee SP, Shin YS, Kang SY, Kim TB, Lee SM. Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review. Immune network. 2022;22(1):e12.
38.Aalberse RC. Structural biology of allergens. Journal of allergy and clinical immunology. 2000;106(2):228-38.
39.Huby RD, Dearman RJ, Kimber I. Why are some proteins allergens? Toxicological Sciences. 2000;55(2):235-46.
40.Zhao J, Li C, Zhao B, Xu P, Xu H, He L. Construction of the recombinant vaccine based on T-cell epitope encoding Der p1 and evaluation on its specific immunotherapy efficacy. Int J Clin Exp Med. 2015;8(4):6436-43.
41.O'hehir R, Young D, Kay A, Lamb J. Cloned human T lymphocytes reactive with Dermatophagoides farinae (house dust mite): a comparison of T-and B-cell antigen recognition. Immunology. 1987;62(4):635.
42.O’Hehir R, Askonas B, Lamb J. Cell culture: lymphocyte clones. Methods of immunological analysis. 1993;3:120-38.
43.Fanuel S, Tabesh S, Mokhtarian K, Saroddiny E, Fazlollahi MR, Pourpak Z, et al. Construction of a recombinant B-cell epitope vaccine based on a Der p1-derived hypoallergen: a bioinformatics approach. Immunotherapy. 2018;10(7):537-53.
44.Frazier A, Schulten V, Hinz D, Oseroff C, Sidney J, Peters B, et al. Allergy-associated T cell epitope repertoires are surprisingly diverse and include non-IgE reactive antigens. World Allergy Organ J. 2014;7(1):26.
45.Zare A, Saremi A, Hajhashemi M, Kardar GA, Moazzeni SM, Pourpak Z, et al. Correlation between serum zinc levels and successful immunotherapy in recurrent spontaneous abortion patients. Journal of human reproductive sciences. 2013;6(2):147-51.
46.O'Hehir RE, Prickett SR, Rolland JM. T Cell Epitope Peptide Therapy for Allergic Diseases. Curr Allergy Asthma Rep. 2016;16(2):14-.
47.Gardner LM, O'Hehir RE, Rolland JM. High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-gamma+ T Cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol. 2004;133(1):1-13.
48.Prickett SR, Rolland JM, O'Hehir RE. Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2015;45(6):1015-26.
49.Marth K, Focke-Tejkl M, Lupinek C, Valenta R, Niederberger V. Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Current treatment options in allergy. 2014;1(1):91-106.
50.Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine. 2012;30(29):4328-35.
51.Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy. 2010;40(3):385-97.
52.Chen KW, Blatt K, Thomas WR, Swoboda I, Valent P, Valenta R, et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. The Journal of allergy and clinical immunology. 2012;130(2):435-43.e4.
53.Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol. 2015;135(5):1207-7.e1-11.
54.Alexander C, Ying S, B. Kay A, Larche M. Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjects. Clinical & Experimental Allergy. 2005;35(1):52-8.
55.Moten D, Kolchakova D, Todorov K, Mladenova T, Dzhambazov B. Design of an Epitope-Based Peptide Vaccine Against the Major Allergen Amb a 11 Using Immunoinformatic Approaches. The Protein Journal. 2022.
56.Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. The FASEB Journal. 2001;15(11):2042-4.
57.Twaroch TE, Focke M, Civaj V, Weber M, Balic N, Mari A, et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. Journal of allergy and clinical immunology. 2011;128(1):178-84. e7.
58.Tabesh S, Fanuel S, Fazlollahi MR, Yekaninejad MS, Kardar GA, Razavi SA. Design and evaluation of a hypoallergenic peptide-based vaccine for Salsola kali allergy. Int Immunopharmacol. 2019;66:62-8.
59.Sánchez-Borges M, Fernandez-Caldas E, Thomas WR, Chapman MD, Lee BW, Caraballo L, et al. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organization Journal. 2017;10(1):1-26.
60.CHAPMAN MD, PLATTS-MILLS E. PURIFICATION AND CHARACTERIZATION OF THE MAJOR ANTIGEN P,'. The Journal of Immunology. 1980;125(2).
61.Chua K. Stewart 6. A., Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM and Turner KJ (1988) Sequence analysis of cDNA coding for a major house dust mite allergen. Der p1. J exp Med.167:175-82.
62.Meno K, Thorsted PB, Ipsen H, Kristensen O, Larsen JN, Spangfort MD, et al. The crystal structure of recombinant proDer p 1, a major house dust mite proteolytic allergen. The Journal of Immunology. 2005;175(6):3835-45.
63.Dumez M-E, Herman J, Campisi V, Galleni M, Jacquet A, Chevigné A. Orchestration of an uncommon maturation cascade of the house dust mite protease allergen quartet. Frontiers in immunology. 2014;5:138.
64.Chevigné A, Barumandzadeh R, Groslambert S, Cloes B, Dehareng D, Filée P, et al. Relationship between propeptide pH unfolding and inhibitory ability during ProDer p 1 activation mechanism. Journal of molecular biology. 2007;374(1):170-85.
65.Chevigné A, Dumez M-E, Dumoulin M, Matagne A, Jacquet A, Galleni M. Comparative study of mature and zymogen mite cysteine protease stability and pH unfolding. Biochimica et Biophysica Acta (BBA)-General Subjects. 2010;1800(9):937-45.
66.Zhang J, Hamilton J, Garrod D, Robinson C. Interactions between mature Der p 1 and its free prodomain indicate membership of a new family of C1 peptidases. Allergy. 2007;62(11):1302-9.
67.Takai T, Mineki R, Nakazawa T, Takaoka M, Yasueda H, Murayama K, et al. Maturation of the activities of recombinant mite allergens Der p 1 and Der f 1, and its implication in the blockade of proteolytic activity. FEBS letters. 2002;531(2):265-72.
68.Jacquet A, Magi M, Petry H, Bollen A. High‐level expression of recombinant house dust mite allergen Der p 1 in Pichia pastoris. Clinical & Experimental Allergy. 2002;32(7):1048-53.
69.Massaer M, Mazzu P, Haumont M, Magi M, Daminet V, Bollen A, et al. High-level expression in mammalian cells of recombinant house dust mite allergen ProDer p 1 with optimized codon usage. International archives of allergy and immunology. 2001;125(1):32-43.
70.Harris J, Mason DE, Li J, Burdick KW, Backes BJ, Chen T, et al. Activity profile of dust mite allergen extract using substrate libraries and functional proteomic microarrays. Chemistry & biology. 2004;11(10):1361-72.
71.tan Deslée G, Charbonnier A-S, Hammad H, Angyalosi G, Tillie-Leblond I, Mantovani A, et al. Involvement of the mannose receptor in the uptake of Der p 1, a major mite allergen, by human dendritic cells. Journal of Allergy and Clinical Immunology. 2002;110(5):763-70.
72.Royer P-J, Emara M, Yang C, Al-Ghouleh A, Tighe P, Jones N, et al. The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. The Journal of Immunology. 2010;185(3):1522-31.
73.De Kivit S, Kraneveld AD, Knippels LM, Van Kooyk Y, Garssen J, Willemsen LE. Intestinal epithelium-derived galectin-9 is involved in the immunomodulating effects of nondigestible oligosaccharides. Journal of Innate Immunity. 2013;5(6):625-38.
74.Dumez M-E, Herman J, Campisi V, Galleni M, Jacquet A, Chevigné A. Orchestration of an Uncommon Maturation Cascade of the House Dust Mite Protease Allergen Quartet. Frontiers in Immunology. 2014;5(138).
75.Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. The Journal of clinical investigation. 1999;104(1):123-33.
76.Valenta R, Karaulov A, Niederberger V, Zhernov Y, Elisyutina O, Campana R, et al. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? The journal of allergy and clinical immunology In practice. 2018;6(6):1845-55.e2.
77.Dua B, Park J, Kim H. Comparison of weight per volume and protein nitrogen units in non-standardized allergen extracts: implications for prescribing subcutaneous immunotherapy. Allergy, Asthma & Clinical Immunology. 2021;17(1):1-10.
78.Cox L. Standardized allergen extracts: past, present and future. Expert review of clinical immunology. 2005;1(4):579-88.
79.Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. Journal of Allergy and Clinical Immunology. 2011;127(1):S1-S55.
80.Dua B, Park J, Kim H. Comparison of Weight Per Volume and Protein Nitrogen Units in Non-standardized Allergen Extracts: Implications for Prescribing Subcutaneous Immunotherapy. 2021.
81.Baselgia S, Doherr M, Mellor P, Torsteinsdottir S, Jermann T, Zurbriggen A, et al. Evaluation of an in vitro sulphidoleukotriene release test for diagnosis of insect bite hypersensitivity in horses. Equine veterinary journal. 2006;38(1):40-6.
82.Langner KF, Darpel KE, Drolet BS, Fischer A, Hampel S, Heselhaus JE, et al. Comparison of cellular and humoral immunoassays for the assessment of summer eczema in horses. Veterinary immunology and immunopathology. 2008;122(1-2):126-37.
83.van der Meide NM, Meulenbroeks C, van Altena C, Schurink A, Ducro BJ, Wagner B, et al. Culicoides obsoletus extract relevant for diagnostics of insect bite hypersensitivity in horses. Veterinary immunology and immunopathology. 2012;149(3-4):245-54.
84.Wagner B, Childs BA, Erb HN. A histamine release assay to identify sensitization to Culicoides allergens in horses with skin hypersensitivity. Veterinary immunology and immunopathology. 2008;126(3-4):302-8.
85.Curin M, Garib V, Valenta R. Single recombinant and purified major allergens and peptides: how they are made and how they change allergy diagnosis and treatment. Annals of Allergy, Asthma & Immunology. 2017;119(3):201-9.
86.Jonsdottir S, Cvitas I, Svansson V, Fettelschloss-Gabriel A, Torsteinsdottir S, Marti E. New strategies for prevention and treatment of insect bite hypersensitivity in horses. Current Dermatology Reports. 2019;8(4):303-12.
87.Novotny EN, White SJ, Wilson AD, Stefánsdóttir SB, Tijhaar E, Jonsdóttir S, et al. Component‐resolved microarray analysis of IgE sensitization profiles to Culicoides recombinant allergens in horses with insect bite hypersensitivity. Allergy. 2021;76(4):1147-57.
88.van der Meide NM, Savelkoul HF, Meulenbroeks C, Ducro BJ, Tijhaar E. Evaluation of a diagnostic ELISA for insect bite hypersensitivity in horses using recombinant Obsoletus complex allergens. The Veterinary Journal. 2014;200(1):31-7.
89.Jensen-Jarolim E, Roth-Walter F, Jordakieva G, Pali-Schöll I. Allergens and Adjuvants in Allergen Immunotherapy for Immune Activation, Tolerance, and Resilience. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(5):1780-9.
90.Yang L, Zhu R. Allergen Preparation in AIT, Now and in the Future. Current Treatment Options in Allergy. 2021:1-13.
91.De Kam P-J, Kramer MF, Shamji MH, Oluwayi K, Heath MD, Jensen-Jarolim E, et al. Dogmas, challenges, and promises in phase III allergen immunotherapy studies. World Allergy Organization Journal. 2021;14(9):100578.
92.Dorofeeva Y, Shilovskiy I, Tulaeva I, Focke‐Tejkl M, Flicker S, Kudlay D, et al. Past, present, and future of allergen immunotherapy vaccines. Allergy. 2021;76(1):131-49.
93.Brunetto B, Tinghino R, Braschi M, Antonicelli L, Pini C, Iacovacci P. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy. 2010;65(2):184-90.
94.Klimek L, Hoffmann H, Renz H, Demoly P, Werfel T, Matricardi P, et al. Diagnostic test allergens used for in vivo diagnosis of allergic diseases are at risk: a European Perspective. Allergy. 2015;70(10):1329-31.
95.Klimek L, Hoffmann HJ, Kugler A, Muraro A, Hellings PW. Impact of changed legislation on skin tests: the present and future. Current opinion in allergy and clinical immunology. 2016;16(5):465-8.
96.Twaroch TE, Curin M, Sterflinger K, Focke-Tejkl M, Swoboda I, Valenta R. Specific antibodies for the detection of Alternaria allergens and the identification of cross-reactive antigens in other fungi. International archives of allergy and immunology. 2016;170(4):269-78.
97.Akkerdaas JH, Wensing M, Knulst AC, Krebitz M, Breiteneder H, de Vries S, et al. How accurate and safe is the diagnosis of hazelnut allergy by means of commercial skin prick test reagents? International archives of allergy and immunology. 2003;132(2):132-40.
98.Sircar G, Saha B, Mandal RS, Pandey N, Saha S, Gupta Bhattacharya S. Purification, cloning and immuno-biochemical characterization of a fungal aspartic protease allergen Rhi o 1 from the airborne mold Rhizopus oryzae. PLoS One. 2015;10(12):e0144547.
99.Snelgrove RJ, Gregory LG, Peiró T, Akthar S, Campbell GA, Walker SA, et al. Alternaria-derived serine protease activity drives IL-33–mediated asthma exacerbations. Journal of allergy and clinical immunology. 2014;134(3):583-92. e6.
100. Balenga NA, Klichinsky M, Xie Z, Chan EC, Zhao M, Jude J, et al. A fungal protease allergen provokes airway hyper-responsiveness in asthma. Nature communications. 2015;6(1):1-13.
101. Casset A, Valenta R, Vrtala S. Allergen content and in vivo allergenic activity of house dust mite extracts. International archives of allergy and immunology. 2013;161(3):287.
102. Bonertz A, Roberts G, Slater J, Bridgewater J, Rabin R, Hoefnagel M, et al. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: an analysis from the EAACI AIT Guidelines Project. Allergy. 2018;73(4):816-26.
103. Chang G-H, Lin Y-S, Hsu K-H, Cheng Y-C, Yang P-R, Tsai M-S, et al. Nasal irrigation with Glycyrrhiza glabra extract for treatment of allergic rhinitis–A study of in vitro, in vivo and clinical trial. Journal of Ethnopharmacology. 2021;275:114116.
104. Ziegler A, Olzhausen J, Hamza E, Stojiljkovic A, Stoffel MH, Garbani M, et al. An allergen-fused dendritic cell-binding peptide enhances in vitro proliferation of equine T-cells and cytokine production. Veterinary Immunology and Immunopathology. 2021:110351.
105. Zhernov Y, Curin M, Khaitov M, Karaulov A, Valenta R. Recombinant allergens for immunotherapy: state of the art. Current opinion in allergy and clinical immunology. 2019;19(4):402.
106. Larsen JM, Bang-Berthelsen CH, Qvortrup K, Sancho AI, Hansen AH, Andersen KIH, et al. Production of allergen-specific immunotherapeutic agents for the treatment of food allergy. Critical Reviews in Biotechnology. 2020;40(6):881-94.
107. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. Journal of Allergy and Clinical Immunology. 2005;116(3):608-13.
108. Yamada Y, Kidoguchi M, Yata A, Nakamura T, Yoshida H, Kato Y, et al. High-yield production of the major birch pollen allergen Bet v 1 with allergen immunogenicity in Nicotiana benthamiana. Frontiers in plant science. 2020;11:344.
109. Jonsdottir S, Torsteinsdottir S, Svansson V, Gudbrandsson J, Stefansdottir SB, Bjornsson JM, et al. Comparison of recombinant Culicoides allergens produced in different expression systems for IgE serology of insect bite hypersensitivity in horses of different origins. Veterinary Immunology and Immunopathology. 2021:110289.
110. Han X, Cao M, Zhou B, Yu C, Liu Y, Peng B, et al. Specifically immobilizing His-tagged allergens to magnetic nanoparticles for fast and quantitative detection of allergen-specific IgE in serum samples. Talanta. 2020;219:121301.
111. da Justa HC, Matsubara FH, de-Bona E, Schemczssen-Graeff Z, Polli NLC, de Mari TL, et al. LALLT (Loxosceles Allergen-Like Toxin) from the venom of Loxosceles intermedia: Recombinant expression in insect cells and characterization as a molecule with allergenic properties. International Journal of Biological Macromolecules. 2020;164:3984-99.
112. Bhowmik M, Sarkar MB, Sarkar RK, Dasgupta A, Saha S, Jana K, et al. Cloning and immunobiochemical analyses on recombinant chymopapain allergen Cari p 2 showing pollen-fruit cross-reaction. Molecular Immunology. 2021;137:42-51.
113. Muthu V, Singh P, Choudhary H, Sehgal IS, Dhooria S, Prasad KT, et al. Diagnostic cutoffs and clinical utility of recombinant Aspergillus fumigatus antigens in the diagnosis of allergic bronchopulmonary aspergillosis. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(2):579-87.
114. Xu LL, Zhang HW, Zhang XM, Lin H, Guo YM, Yu C, et al. Natural Shrimp (Litopenaeus vannamei) tropomyosin shows higher allergic properties than recombinant ones as compared through SWATH-MS-based proteomics and immunological response. Journal of Agricultural and Food Chemistry. 2020;68(41):11553-67.
115. Mohammadi M, Mokhtarian K, Kardar GA, Farrokhi S, Sadroddiny E, Khorramizadeh MR, et al. Expression of recombinant parvalbumin from wolf-herring fish and determination of its IgE-binding capability. Food and Agricultural Immunology. 2017;28(4):573-85.
116. Akimoto S, Yokooji T, Ogino R, Chinuki Y, Taogoshi T, Adachi A, et al. Identification of allergens for food-dependent exercise-induced anaphylaxis to shrimp. Scientific reports. 2021;11(1):1-9.
117. Kaeswurm JA, Nestl B, Richter SM, Emperle M, Buchweitz M. Purification and characterization of recombinant expressed apple allergen Mal d 1. Methods and Protocols. 2021;4(1):3.
118. Huang Y, Li Z, Wu Y, Guo Y, Pavase TR, Chen G, et al. Comparison of immunological properties of recombinant and natural turbot (Scophthalmus maximus) parvalbumin. European Food Research and Technology. 2021:1-13.
119. Coquet JM, Stark JM, Liu J, Tibbitt CA, Christian M, Ma J, et al. Sublingual allergen immunotherapy with recombinant dog allergens prevents airway hyperresponsiveness in a model of asthma marked by vigorous TH2 and TH17 cell responses. bioRxiv. 2021.
120. Jonsdottir S, Stefansdottir SB, Kristinarson SB, Svansson V, Bjornsson JM, Runarsdottir A, et al. Barley produced Culicoides allergens are suitable for monitoring the immune response of horses immunized with E. coli expressed allergens. Veterinary immunology and immunopathology. 2018;201:32-7.
121. Magnusdottir A, Vidarsson H, Björnsson JM, Örvar BL. Barley grains for the production of endotoxin-free growth factors. Trends in biotechnology. 2013;31(10):572-80.
2.Migueres M, Dávila I, Frati F, Azpeitia A, Jeanpetit Y, Lhéritier-Barrand M, et al. Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease. Clin Transl Allergy. 2014;4:16.
3.Pawankar R, Baena-Cagnani CE, Bousquet J, Canonica GW, Cruz AA, Kaliner MA, et al. State of world allergy report 2008: allergy and chronic respiratory diseases. World Allergy Organ J. 2008;1(6 Suppl):S4-S17.
4.Valenta R, Karaulov A, Niederberger V, Zhernov Y, Elisyutina O, Campana R, et al. Allergen extracts for in vivo diagnosis and treatment of allergy: is there a future? The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(6):1845-55. e2.
5.Niederberger V, Eckl-Dorna J, Pauli G. Recombinant allergen-based provocation testing. Methods. 2014;66(1):96-105.
6.Eckl-Dorna J, Klein B, Reichenauer TG, Niederberger V, Valenta R. Exposure of rye (Secale cereale) cultivars to elevated ozone levels increases the allergen content in pollen. Journal of Allergy and Clinical Immunology. 2010;126(6):1315-7.
7.Forte G, Petrucci F, Bocca B. Metal allergens of growing significance: epidemiology, immunotoxicology, strategies for testing and prevention. Inflammation & allergy drug targets. 2008;7(3):145-62.
8.Bacher P, Scheffold A. The effect of regulatory T cells on tolerance to airborne allergens and allergen immunotherapy. The Journal of allergy and clinical immunology. 2018;142(6):1697-709.
9.Burge HA, Rogers CA. Outdoor allergens. Environmental health perspectives. 2000;108 Suppl 4(Suppl 4):653-9.
10.Ring J, Gutermuth J. 100 years of hyposensitization: history of allergen‐specific immunotherapy (ASIT). Allergy. 2011;66(6):713-24.
11.Ostrom NK, editor The history and progression of treatments for allergic rhinitis. Allergy & Asthma Proceedings; 2014.
12.Vatti RR, Ali F, Teuber S, Chang C, Gershwin ME. Hypersensitivity reactions to corticosteroids. Clinical reviews in allergy & immunology. 2014;47(1):26-37.
13.Settipane RA, Schwindt C. Allergic rhinitis. American journal of rhinology & allergy. 2013;27(3_suppl):S52-S5.
14.Vieths S, Zimmer J, Bridgewater J, Ferreira F, van Ree R, Rabin RL. The History, Present and Future of Allergen Standardization in the United States and Europe. Frontiers in immunology. 2021:3648.
15.Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Current opinion in immunology. 1995;7(6):751-6.
16.Valenta R. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy. 1999;29:896-904.
17.Kucuksezer UC, Ozdemir C, Cevhertas L, Ogulur I, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergology international : official journal of the Japanese Society of Allergology. 2020;69(4):549-60.
18.Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17-.
19.Noon L. Prophylactic inoculation against hayfever. Lancet i: 1572–1573. Freeman J.(1911) Further observations of the treatment of hay fever by …; 1911.
20.Johansson S. The history of IgE: from discovery to 2010. Current allergy and asthma reports. 2011;11(2):173-7.
21.Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children—a 14-year study. Pediatrics. 968;42(5):793-802.
22.Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. New England Journal of Medicine. 1978;299(4):157-61.
23.Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy. 1997;27(8):860-7.
24.Makatsori M, Pfaar O, Lleonart R, Calderon MA. Recombinant allergen immunotherapy: clinical evidence of efficacy--a review. Curr Allergy Asthma Rep. 2013;13(4):371-80.
25.Gold MJ, Antignano F, Halim TY, Hirota JA, Blanchet M-R, Zaph C, et al. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. Journal of Allergy and Clinical Immunology. 2014;133(4):1142-8. e5.
26.Scadding G, Durham S. Mechanisms of sublingual immunotherapy. The Journal of asthma : official journal of the Association for the Care of Asthma. 2009;46(4):322-34.
27.Scadding G, Durham S. Mechanisms of sublingual immunotherapy. Journal of Asthma. 2009;46(4):322-34.
28.Morris AE, Marshall GD. Safety of allergen immunotherapy: a review of premedication and dose adjustment. Immunotherapy. 2012;4(3):315-22.
29.Baron‐Bodo V, Batard T, Nguyen H, Frereux M, Horiot S, Harwanegg C, et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clinical & Experimental Allergy. 2012;42(10):1510-8.
30.Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. Journal of Allergy and Clinical Immunology. 2010;126(5):969-75.
31.Yang L, Zhu R. Immunotherapy of house dust mite allergy. Hum Vaccin Immunother. 2017;13(10):2390-6.
32.Cox L. Biologics and Allergy Immunotherapy in the Treatment of Allergic Diseases. Immunology and Allergy Clinics. 2020;40(4):687-700.
33.van de Veen W, Akdis M. Tolerance mechanisms of AIT. Allergy. 2020;75(5):1017-8.
34.Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. Journal of allergy and clinical immunology. 2004;113(6):1117-21.
35.Windom HH, Lockey RF. An update on the safety of specific immunotherapy. Current opinion in allergy and clinical immunology. 2008;8(6):571-6.
36.Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunology today. 1991;12(8):256-7.
37.Lee SP, Shin YS, Kang SY, Kim TB, Lee SM. Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review. Immune network. 2022;22(1):e12.
38.Aalberse RC. Structural biology of allergens. Journal of allergy and clinical immunology. 2000;106(2):228-38.
39.Huby RD, Dearman RJ, Kimber I. Why are some proteins allergens? Toxicological Sciences. 2000;55(2):235-46.
40.Zhao J, Li C, Zhao B, Xu P, Xu H, He L. Construction of the recombinant vaccine based on T-cell epitope encoding Der p1 and evaluation on its specific immunotherapy efficacy. Int J Clin Exp Med. 2015;8(4):6436-43.
41.O'hehir R, Young D, Kay A, Lamb J. Cloned human T lymphocytes reactive with Dermatophagoides farinae (house dust mite): a comparison of T-and B-cell antigen recognition. Immunology. 1987;62(4):635.
42.O’Hehir R, Askonas B, Lamb J. Cell culture: lymphocyte clones. Methods of immunological analysis. 1993;3:120-38.
43.Fanuel S, Tabesh S, Mokhtarian K, Saroddiny E, Fazlollahi MR, Pourpak Z, et al. Construction of a recombinant B-cell epitope vaccine based on a Der p1-derived hypoallergen: a bioinformatics approach. Immunotherapy. 2018;10(7):537-53.
44.Frazier A, Schulten V, Hinz D, Oseroff C, Sidney J, Peters B, et al. Allergy-associated T cell epitope repertoires are surprisingly diverse and include non-IgE reactive antigens. World Allergy Organ J. 2014;7(1):26.
45.Zare A, Saremi A, Hajhashemi M, Kardar GA, Moazzeni SM, Pourpak Z, et al. Correlation between serum zinc levels and successful immunotherapy in recurrent spontaneous abortion patients. Journal of human reproductive sciences. 2013;6(2):147-51.
46.O'Hehir RE, Prickett SR, Rolland JM. T Cell Epitope Peptide Therapy for Allergic Diseases. Curr Allergy Asthma Rep. 2016;16(2):14-.
47.Gardner LM, O'Hehir RE, Rolland JM. High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-gamma+ T Cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol. 2004;133(1):1-13.
48.Prickett SR, Rolland JM, O'Hehir RE. Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2015;45(6):1015-26.
49.Marth K, Focke-Tejkl M, Lupinek C, Valenta R, Niederberger V. Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Current treatment options in allergy. 2014;1(1):91-106.
50.Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine. 2012;30(29):4328-35.
51.Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy. 2010;40(3):385-97.
52.Chen KW, Blatt K, Thomas WR, Swoboda I, Valent P, Valenta R, et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. The Journal of allergy and clinical immunology. 2012;130(2):435-43.e4.
53.Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol. 2015;135(5):1207-7.e1-11.
54.Alexander C, Ying S, B. Kay A, Larche M. Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjects. Clinical & Experimental Allergy. 2005;35(1):52-8.
55.Moten D, Kolchakova D, Todorov K, Mladenova T, Dzhambazov B. Design of an Epitope-Based Peptide Vaccine Against the Major Allergen Amb a 11 Using Immunoinformatic Approaches. The Protein Journal. 2022.
56.Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. The FASEB Journal. 2001;15(11):2042-4.
57.Twaroch TE, Focke M, Civaj V, Weber M, Balic N, Mari A, et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. Journal of allergy and clinical immunology. 2011;128(1):178-84. e7.
58.Tabesh S, Fanuel S, Fazlollahi MR, Yekaninejad MS, Kardar GA, Razavi SA. Design and evaluation of a hypoallergenic peptide-based vaccine for Salsola kali allergy. Int Immunopharmacol. 2019;66:62-8.
59.Sánchez-Borges M, Fernandez-Caldas E, Thomas WR, Chapman MD, Lee BW, Caraballo L, et al. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organization Journal. 2017;10(1):1-26.
60.CHAPMAN MD, PLATTS-MILLS E. PURIFICATION AND CHARACTERIZATION OF THE MAJOR ANTIGEN P,'. The Journal of Immunology. 1980;125(2).
61.Chua K. Stewart 6. A., Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM and Turner KJ (1988) Sequence analysis of cDNA coding for a major house dust mite allergen. Der p1. J exp Med.167:175-82.
62.Meno K, Thorsted PB, Ipsen H, Kristensen O, Larsen JN, Spangfort MD, et al. The crystal structure of recombinant proDer p 1, a major house dust mite proteolytic allergen. The Journal of Immunology. 2005;175(6):3835-45.
63.Dumez M-E, Herman J, Campisi V, Galleni M, Jacquet A, Chevigné A. Orchestration of an uncommon maturation cascade of the house dust mite protease allergen quartet. Frontiers in immunology. 2014;5:138.
64.Chevigné A, Barumandzadeh R, Groslambert S, Cloes B, Dehareng D, Filée P, et al. Relationship between propeptide pH unfolding and inhibitory ability during ProDer p 1 activation mechanism. Journal of molecular biology. 2007;374(1):170-85.
65.Chevigné A, Dumez M-E, Dumoulin M, Matagne A, Jacquet A, Galleni M. Comparative study of mature and zymogen mite cysteine protease stability and pH unfolding. Biochimica et Biophysica Acta (BBA)-General Subjects. 2010;1800(9):937-45.
66.Zhang J, Hamilton J, Garrod D, Robinson C. Interactions between mature Der p 1 and its free prodomain indicate membership of a new family of C1 peptidases. Allergy. 2007;62(11):1302-9.
67.Takai T, Mineki R, Nakazawa T, Takaoka M, Yasueda H, Murayama K, et al. Maturation of the activities of recombinant mite allergens Der p 1 and Der f 1, and its implication in the blockade of proteolytic activity. FEBS letters. 2002;531(2):265-72.
68.Jacquet A, Magi M, Petry H, Bollen A. High‐level expression of recombinant house dust mite allergen Der p 1 in Pichia pastoris. Clinical & Experimental Allergy. 2002;32(7):1048-53.
69.Massaer M, Mazzu P, Haumont M, Magi M, Daminet V, Bollen A, et al. High-level expression in mammalian cells of recombinant house dust mite allergen ProDer p 1 with optimized codon usage. International archives of allergy and immunology. 2001;125(1):32-43.
70.Harris J, Mason DE, Li J, Burdick KW, Backes BJ, Chen T, et al. Activity profile of dust mite allergen extract using substrate libraries and functional proteomic microarrays. Chemistry & biology. 2004;11(10):1361-72.
71.tan Deslée G, Charbonnier A-S, Hammad H, Angyalosi G, Tillie-Leblond I, Mantovani A, et al. Involvement of the mannose receptor in the uptake of Der p 1, a major mite allergen, by human dendritic cells. Journal of Allergy and Clinical Immunology. 2002;110(5):763-70.
72.Royer P-J, Emara M, Yang C, Al-Ghouleh A, Tighe P, Jones N, et al. The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. The Journal of Immunology. 2010;185(3):1522-31.
73.De Kivit S, Kraneveld AD, Knippels LM, Van Kooyk Y, Garssen J, Willemsen LE. Intestinal epithelium-derived galectin-9 is involved in the immunomodulating effects of nondigestible oligosaccharides. Journal of Innate Immunity. 2013;5(6):625-38.
74.Dumez M-E, Herman J, Campisi V, Galleni M, Jacquet A, Chevigné A. Orchestration of an Uncommon Maturation Cascade of the House Dust Mite Protease Allergen Quartet. Frontiers in Immunology. 2014;5(138).
75.Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. The Journal of clinical investigation. 1999;104(1):123-33.
76.Valenta R, Karaulov A, Niederberger V, Zhernov Y, Elisyutina O, Campana R, et al. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? The journal of allergy and clinical immunology In practice. 2018;6(6):1845-55.e2.
77.Dua B, Park J, Kim H. Comparison of weight per volume and protein nitrogen units in non-standardized allergen extracts: implications for prescribing subcutaneous immunotherapy. Allergy, Asthma & Clinical Immunology. 2021;17(1):1-10.
78.Cox L. Standardized allergen extracts: past, present and future. Expert review of clinical immunology. 2005;1(4):579-88.
79.Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. Journal of Allergy and Clinical Immunology. 2011;127(1):S1-S55.
80.Dua B, Park J, Kim H. Comparison of Weight Per Volume and Protein Nitrogen Units in Non-standardized Allergen Extracts: Implications for Prescribing Subcutaneous Immunotherapy. 2021.
81.Baselgia S, Doherr M, Mellor P, Torsteinsdottir S, Jermann T, Zurbriggen A, et al. Evaluation of an in vitro sulphidoleukotriene release test for diagnosis of insect bite hypersensitivity in horses. Equine veterinary journal. 2006;38(1):40-6.
82.Langner KF, Darpel KE, Drolet BS, Fischer A, Hampel S, Heselhaus JE, et al. Comparison of cellular and humoral immunoassays for the assessment of summer eczema in horses. Veterinary immunology and immunopathology. 2008;122(1-2):126-37.
83.van der Meide NM, Meulenbroeks C, van Altena C, Schurink A, Ducro BJ, Wagner B, et al. Culicoides obsoletus extract relevant for diagnostics of insect bite hypersensitivity in horses. Veterinary immunology and immunopathology. 2012;149(3-4):245-54.
84.Wagner B, Childs BA, Erb HN. A histamine release assay to identify sensitization to Culicoides allergens in horses with skin hypersensitivity. Veterinary immunology and immunopathology. 2008;126(3-4):302-8.
85.Curin M, Garib V, Valenta R. Single recombinant and purified major allergens and peptides: how they are made and how they change allergy diagnosis and treatment. Annals of Allergy, Asthma & Immunology. 2017;119(3):201-9.
86.Jonsdottir S, Cvitas I, Svansson V, Fettelschloss-Gabriel A, Torsteinsdottir S, Marti E. New strategies for prevention and treatment of insect bite hypersensitivity in horses. Current Dermatology Reports. 2019;8(4):303-12.
87.Novotny EN, White SJ, Wilson AD, Stefánsdóttir SB, Tijhaar E, Jonsdóttir S, et al. Component‐resolved microarray analysis of IgE sensitization profiles to Culicoides recombinant allergens in horses with insect bite hypersensitivity. Allergy. 2021;76(4):1147-57.
88.van der Meide NM, Savelkoul HF, Meulenbroeks C, Ducro BJ, Tijhaar E. Evaluation of a diagnostic ELISA for insect bite hypersensitivity in horses using recombinant Obsoletus complex allergens. The Veterinary Journal. 2014;200(1):31-7.
89.Jensen-Jarolim E, Roth-Walter F, Jordakieva G, Pali-Schöll I. Allergens and Adjuvants in Allergen Immunotherapy for Immune Activation, Tolerance, and Resilience. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(5):1780-9.
90.Yang L, Zhu R. Allergen Preparation in AIT, Now and in the Future. Current Treatment Options in Allergy. 2021:1-13.
91.De Kam P-J, Kramer MF, Shamji MH, Oluwayi K, Heath MD, Jensen-Jarolim E, et al. Dogmas, challenges, and promises in phase III allergen immunotherapy studies. World Allergy Organization Journal. 2021;14(9):100578.
92.Dorofeeva Y, Shilovskiy I, Tulaeva I, Focke‐Tejkl M, Flicker S, Kudlay D, et al. Past, present, and future of allergen immunotherapy vaccines. Allergy. 2021;76(1):131-49.
93.Brunetto B, Tinghino R, Braschi M, Antonicelli L, Pini C, Iacovacci P. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy. 2010;65(2):184-90.
94.Klimek L, Hoffmann H, Renz H, Demoly P, Werfel T, Matricardi P, et al. Diagnostic test allergens used for in vivo diagnosis of allergic diseases are at risk: a European Perspective. Allergy. 2015;70(10):1329-31.
95.Klimek L, Hoffmann HJ, Kugler A, Muraro A, Hellings PW. Impact of changed legislation on skin tests: the present and future. Current opinion in allergy and clinical immunology. 2016;16(5):465-8.
96.Twaroch TE, Curin M, Sterflinger K, Focke-Tejkl M, Swoboda I, Valenta R. Specific antibodies for the detection of Alternaria allergens and the identification of cross-reactive antigens in other fungi. International archives of allergy and immunology. 2016;170(4):269-78.
97.Akkerdaas JH, Wensing M, Knulst AC, Krebitz M, Breiteneder H, de Vries S, et al. How accurate and safe is the diagnosis of hazelnut allergy by means of commercial skin prick test reagents? International archives of allergy and immunology. 2003;132(2):132-40.
98.Sircar G, Saha B, Mandal RS, Pandey N, Saha S, Gupta Bhattacharya S. Purification, cloning and immuno-biochemical characterization of a fungal aspartic protease allergen Rhi o 1 from the airborne mold Rhizopus oryzae. PLoS One. 2015;10(12):e0144547.
99.Snelgrove RJ, Gregory LG, Peiró T, Akthar S, Campbell GA, Walker SA, et al. Alternaria-derived serine protease activity drives IL-33–mediated asthma exacerbations. Journal of allergy and clinical immunology. 2014;134(3):583-92. e6.
100. Balenga NA, Klichinsky M, Xie Z, Chan EC, Zhao M, Jude J, et al. A fungal protease allergen provokes airway hyper-responsiveness in asthma. Nature communications. 2015;6(1):1-13.
101. Casset A, Valenta R, Vrtala S. Allergen content and in vivo allergenic activity of house dust mite extracts. International archives of allergy and immunology. 2013;161(3):287.
102. Bonertz A, Roberts G, Slater J, Bridgewater J, Rabin R, Hoefnagel M, et al. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: an analysis from the EAACI AIT Guidelines Project. Allergy. 2018;73(4):816-26.
103. Chang G-H, Lin Y-S, Hsu K-H, Cheng Y-C, Yang P-R, Tsai M-S, et al. Nasal irrigation with Glycyrrhiza glabra extract for treatment of allergic rhinitis–A study of in vitro, in vivo and clinical trial. Journal of Ethnopharmacology. 2021;275:114116.
104. Ziegler A, Olzhausen J, Hamza E, Stojiljkovic A, Stoffel MH, Garbani M, et al. An allergen-fused dendritic cell-binding peptide enhances in vitro proliferation of equine T-cells and cytokine production. Veterinary Immunology and Immunopathology. 2021:110351.
105. Zhernov Y, Curin M, Khaitov M, Karaulov A, Valenta R. Recombinant allergens for immunotherapy: state of the art. Current opinion in allergy and clinical immunology. 2019;19(4):402.
106. Larsen JM, Bang-Berthelsen CH, Qvortrup K, Sancho AI, Hansen AH, Andersen KIH, et al. Production of allergen-specific immunotherapeutic agents for the treatment of food allergy. Critical Reviews in Biotechnology. 2020;40(6):881-94.
107. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. Journal of Allergy and Clinical Immunology. 2005;116(3):608-13.
108. Yamada Y, Kidoguchi M, Yata A, Nakamura T, Yoshida H, Kato Y, et al. High-yield production of the major birch pollen allergen Bet v 1 with allergen immunogenicity in Nicotiana benthamiana. Frontiers in plant science. 2020;11:344.
109. Jonsdottir S, Torsteinsdottir S, Svansson V, Gudbrandsson J, Stefansdottir SB, Bjornsson JM, et al. Comparison of recombinant Culicoides allergens produced in different expression systems for IgE serology of insect bite hypersensitivity in horses of different origins. Veterinary Immunology and Immunopathology. 2021:110289.
110. Han X, Cao M, Zhou B, Yu C, Liu Y, Peng B, et al. Specifically immobilizing His-tagged allergens to magnetic nanoparticles for fast and quantitative detection of allergen-specific IgE in serum samples. Talanta. 2020;219:121301.
111. da Justa HC, Matsubara FH, de-Bona E, Schemczssen-Graeff Z, Polli NLC, de Mari TL, et al. LALLT (Loxosceles Allergen-Like Toxin) from the venom of Loxosceles intermedia: Recombinant expression in insect cells and characterization as a molecule with allergenic properties. International Journal of Biological Macromolecules. 2020;164:3984-99.
112. Bhowmik M, Sarkar MB, Sarkar RK, Dasgupta A, Saha S, Jana K, et al. Cloning and immunobiochemical analyses on recombinant chymopapain allergen Cari p 2 showing pollen-fruit cross-reaction. Molecular Immunology. 2021;137:42-51.
113. Muthu V, Singh P, Choudhary H, Sehgal IS, Dhooria S, Prasad KT, et al. Diagnostic cutoffs and clinical utility of recombinant Aspergillus fumigatus antigens in the diagnosis of allergic bronchopulmonary aspergillosis. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(2):579-87.
114. Xu LL, Zhang HW, Zhang XM, Lin H, Guo YM, Yu C, et al. Natural Shrimp (Litopenaeus vannamei) tropomyosin shows higher allergic properties than recombinant ones as compared through SWATH-MS-based proteomics and immunological response. Journal of Agricultural and Food Chemistry. 2020;68(41):11553-67.
115. Mohammadi M, Mokhtarian K, Kardar GA, Farrokhi S, Sadroddiny E, Khorramizadeh MR, et al. Expression of recombinant parvalbumin from wolf-herring fish and determination of its IgE-binding capability. Food and Agricultural Immunology. 2017;28(4):573-85.
116. Akimoto S, Yokooji T, Ogino R, Chinuki Y, Taogoshi T, Adachi A, et al. Identification of allergens for food-dependent exercise-induced anaphylaxis to shrimp. Scientific reports. 2021;11(1):1-9.
117. Kaeswurm JA, Nestl B, Richter SM, Emperle M, Buchweitz M. Purification and characterization of recombinant expressed apple allergen Mal d 1. Methods and Protocols. 2021;4(1):3.
118. Huang Y, Li Z, Wu Y, Guo Y, Pavase TR, Chen G, et al. Comparison of immunological properties of recombinant and natural turbot (Scophthalmus maximus) parvalbumin. European Food Research and Technology. 2021:1-13.
119. Coquet JM, Stark JM, Liu J, Tibbitt CA, Christian M, Ma J, et al. Sublingual allergen immunotherapy with recombinant dog allergens prevents airway hyperresponsiveness in a model of asthma marked by vigorous TH2 and TH17 cell responses. bioRxiv. 2021.
120. Jonsdottir S, Stefansdottir SB, Kristinarson SB, Svansson V, Bjornsson JM, Runarsdottir A, et al. Barley produced Culicoides allergens are suitable for monitoring the immune response of horses immunized with E. coli expressed allergens. Veterinary immunology and immunopathology. 2018;201:32-7.
121. Magnusdottir A, Vidarsson H, Björnsson JM, Örvar BL. Barley grains for the production of endotoxin-free growth factors. Trends in biotechnology. 2013;31(10):572-80.
| Files | ||
| Issue | Vol 21 No 5 (2022) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijaai.v21i5.11038 | |
| Keywords | ||
| Allergy Allergen-specific immunotherapy Immunotherapy Recombinant allergen | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Asoudeh Moghanloo S, Forouzanfar M, Jafarinia M, Fazlollahi MR, Kardar GA. A Comprehensive Overview of Allergen-specific Immunotherapy Types, Recombinant and Natural Extract Allergens in the Diagnosis and Treatment of Allergies. Iran J Allergy Asthma Immunol. 2022;21(5):494-511.
